Skip to content
Recall Observatory FDA recall evidence

Exact FDA event identifier

Event 90112

1 recalled-product record grouped only because every row carries this exact official event ID.

Open FDA event record

Event summary

Timeline bucket
May 02, 2022
Product types
Drug
Classifications
Class II
Statuses
Terminated
Recalling firm wording
Amgen, Inc.

Dossier provenance

Source snapshots represented here

  • openFDA Drug Enforcement Report-date coverage June 20, 2012–July 08, 2026 Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.

Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.

How coverage and grouping work

Complete imported group

Every recalled product in this event

1 official enforcement rows

Product dates, classifications, firms, and source wording remain attached to their individual rows. Opening this dossier never hides products that did not match a prior timeline filter.

drug · product 1 of 1

MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01

D-0855-2022
Recall number
D-0855-2022
Initiated
May 02, 2022
Classification
Class II
Status
Terminated
Recalling firm
Amgen, Inc.
Quantity
15,823

App-derived interpretation

Unknown reason.no_named_rule · v1.0.0
Defective container: loose crimp defect, potential loss of container integrity.

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Defective container: loose crimp defect, potential loss of container integrity.

Code information

Lots: 1142258, 1143196, Exp. 09/24

Distribution pattern

Nationwide in the USA, Egypt and Lithuania.